1 Here,
we developed 3D cell-line-based models of human syncytiotroph
2 We developed a 16-item model.
3 We developed a cell delivery strategy based on a supramolecul
4 To quantify the substructure of FAs,
we developed a clustering method based on expectation maximiz
5 We developed a genetic toolkit to study MT dynamics and funct
6 Here
we developed a genome-wide functional screen to interrogate t
7 To address this problem,
we developed a highly multiplexed single-cell DNA sequencing
8 tigate the contribution of the TL to intrinsic termination,
we developed a kinetic assay that distinguishes effects of TL
9 To model hydrostatic pressure-induced edema in vitro,
we developed a method of applied pressure to the basolateral
10 We developed a method to directly capture lipid antigens with
11 We developed a multiscale model of fibrinolysis that includes
12 We developed a new MALS methodology that has overcome the lon
13 We developed a new method (called REPPS) for incorporating ex
14 o study the role of neutrophils in LPS-induced endotoxemia,
we developed a new mouse model, PMN(DTR) mice, in which injec
15 We developed a new multivariable linear model for GFR using s
16 We developed a novel analytical framework for mapping and tes
17 To investigate this claim,
we developed a novel assay that allows for parallel profiling
18 We developed a novel method to compute gene-level P-values (f
19 We developed a novel methodology for burden estimation and pr
20 We developed a panel of tunable expression platforms for the
21 We developed a platform for microfluidics-assisted cell scree
22 Here
we developed a population-level microsatellite profiling appr
23 In this work,
we developed a rice gene co-expression network for anther dev
24 Here,
we developed a sensitive and accurate multiplex miRNA profili
25 Here,
we developed a sensitive sandwich enzyme-linked immunosorbent
26 Previously
we developed a structure-based method for prediction of trans
27 To overcome this barrier,
we developed a synthetic-biology approach based on a techniqu
28 loration of aquatic environments (surface and groundwater),
we developed a technique for field continuous measurements of
29 ts of increased CD39 in an in vivo cerebral ischemia model,
we developed a transgenic mouse expressing human CD39 (hCD39)
30 We developed a transmission-dynamic model on a dynamic networ
31 We developed a two-alternative forced-choice task in an autom
32 To exploit this dual concept,
we developed agents exerting partial FXR agonism and sEH inhi
33 ics of structural variants and their effects on phenotypes,
we developed an approach to mapping structural variants that
34 In this work,
we developed an aptamer/graphene-based electrochemical biosen
35 We developed an efficient cell culture system and isolated HE
36 We developed an evolutionary game theory model using Lotka-Vo
37 To address this issue,
we developed an ITC empirical response model (ITC-ERM) that q
38 Based on this dataset,
we developed and compared 2-class and 3-class DILI prediction
39 We developed and performed resistome analysis, an unbiased ap
40 INTERPRETATION:
We developed and validated a novel clinical prediction model
41 We developed and validated a rapid, sensitive, and robust met
42 Therefore,
we developed biodegradable polymeric microspheres for the sus
43 We developed core shell lipid-polymer hybrid nanoparticles (C
44 Here
we developed covariates for multiphenotype studies (CMS), an
45 tools typically miss these position-specific short motifs,
we developed kpLogo, a probability-based logo tool for integr
46 ation remains a bottleneck of modern untargeted lipidomics,
we developed LipidHunter, a new open source software for the
47 We developed molecular assays and portable optical imaging de
48 Using this approach
we developed quantitative motifs for a selection of kinases f
49 Upon completion of follow-up studies,
we developed the working model that synaptic plasticity in th
50 We developed Yet Another RNA Normalization software pipeline